### "And Now We Know!"

Lessons from establishing North Dakota's first Cellular Therapy Laboratory

Nicholas Gau, MD

Medical Director, Transfusion Medicine & Cellular Therapy

Sanford Health Fargo



### Objectives

- 1. Define key terms relevant to cellular therapy and bone marrow transplantation.
- 2. List laboratory equipment commonly used by a hospital cellular therapy lab in support of bone marrow transplant.
- 3. Name the accrediting bodies with standards pertinent to cellular therapy labs.
- 4. List key people and services inside and outside of the laboratory required for a successful transplant program.





# Hematopoietic Stem Cell Transplant: A Local Need


- Observed incidence, per 100,000 persons (US, 2018)<sup>1</sup>:
  - Multiple myeloma 6.4
  - Non-Hodgkin's lymphoma 18.5
  - Leukemia 12.7
- North Dakota population (est. July 2021)<sup>2</sup>:
  - 774,948



x = HSCT program

### Background: HSCT

- Synonyms:
  - Hematopoietic Stem Cell Transplant (HSCT)
  - Stem Cell Transplant
  - Bone Marrow Transplant (BMT)
- HSCT consists of conditioning chemotherapy, followed by infusion of liquid cell product
- Engraftment: sustained, measurable evidence of hematopoiesis





## Background: HSCT Donors & Sources

- Two main categories of HSCT based on cell donor:
  - Autologous (donate for self)
  - Allogeneic (donate for other)
- Sources of HSCs:
  - Bone marrow
  - Umbilical cord blood
  - Peripheral blood (apheresis)



## Background: What is Cellular Therapy?

- Cellular therapy: the use of human cells, tissues, or cell & tissue-based products (HCT/Ps) to treat, or support treatment, of disease
- HCT/Ps are regulated as biologics by the US Food & Drug Administration (FDA)
- Growing field that includes:
  - Cell products for HSC/BMT
  - Immune effector cells (e.g. CAR-T cells)
  - Orthobiologics (mesenchymal stem cells, MSCs)
- Does <u>not</u> include blood, blood components, and whole organs




# Background: What does a Cellular Therapy Lab (CTL) do?

- Manufactures HCT/Ps as needed for customers:
  - Cell recovery (collection/isolation)
  - Product processing/modification, cell expansion
  - Labeling
  - Storage
  - · Distribution for use
  - Shipping/receiving
- Compliance with Good Tissue Practice (GTP; 21 CFR 1271) and Good Manufacturing Practice (GMP; 21 CFR 600), as applicable
- Accrediting bodies: Foundation for Accreditation of Cellular Therapy (FACT), AABB, CAP







### Not all CTLs are alike!



https://www.labmanager.com/product-news/ge-healthcare-launches-multifunctional-cell-processing-system-4292





Q How do I start up a stem cell lab?

X



- A how to set up a stem cell lab
- can stem cells be made in a lab
- Q how are stem cells made in a lab
- A how to grow cells in a lab

Google Search

I'm Feeling Lucky

Report inappropriate predictions



# Step 1: Setting Goals

- Sanford Health Fargo wants to establish FACT-accredited:
  - 1) Autologous HSCT program
  - 2) Allogeneic HSCT program
  - 3) CAR-T program
  - 4) Apheresis collection facility
  - 5) Bone marrow collection facility



### Are these goals attainable, and when?

- 2019 Expert Consultant Review Findings:
  - Adequate patient volume in region
  - Provided equipment list, cost estimates
  - Starting point for timelines, budgeting, to-do lists
- Focused goals:
  - Perform first autologous HSCT at Sanford Fargo in July, 2021
  - Obtain FACT accreditation for auto HSCT, allo HSCT, and CAR-T all at once (estimated 2024)



### Step 2: Assemble a Team

- FACT-required positions:
  - BMT Clinical Program Medical Director
  - Apheresis & Processing Facility Medical Directors
  - BMT Program Quality Manager
  - Adequate staff trained for inpatient care, apheresis collection, and laboratory manufacturing
- Need a "quarterback" keep whole team working toward goal
- Need "coaches" knowledgeable in HSCT and FACT standards



### Sanford's Starting Lineup...

- "Quarterback" Director of Advanced Therapeutics & Research (RN)
- "Coach" expert consultant with FACT inspector experience (RN)
- Directors:
  - Interim Program Director Hematology-Oncology physician
  - Apheresis & CTL Director BB/TM trained physician
- CTL Techs: two chosen with ~3 years blood bank experience
- Lab Quality Specialist assigned to CTL





### Step 3: Create a Road Map

- Envision what the process might look like given existing processes, available tools and resources
- Representatives from all relevant groups (lab, oncology, facilities, IT, etc.) helps identify problems & solutions
- Key to do <u>before</u> writing policies & procedures



# Auto-HSCT Road Map



#### **Patient evaluation**

- Referral process
- BMT visits (multiple)
- Labs & diagnostics
- Evaluation by other specialists as needed
- Multidisciplinary candidacy meeting
- Questions: acceptance criteria?
   Which insurers will work with us?



#### Cell Collection

- Need catheter placement
- Borrow apheresis machines from dialysis
- Questions: Where to perform?
- Whose staff performs?
- Staff training?
- Order sets and documentation flowsheets?
- Patient safety parameters?



#### **Cell Processing**

- Build lab at Broadway Medical Campus
- Utilize existing labs to perform necessary product testing
- Questions: Equipment and supplies to purchase?
- How to train staff?
- •LIS vs. paper documentation?
- Materials for validation?



#### **Transplant**

- Occur on inpatient oncology floor
- Patient hospitalized from conditioning chemo through neutrophil engraftment (2-3 weeks)
- Questions:
- Are current rooms sufficient?
- Pharmacy experienced with required chemo regimens?
- How to document in the EMR?
- Staff training?





# What "extras" will an auto-HSCT patient need?

- Specialists to evaluate & manage other medical comorbidities
- Facilities: positive pressure inpatient rooms, filtered water for bathing
- Long-term lodging (~2 weeks) for close post-transplant follow up
- Allied health professionals: dietician, psychologist, financial advocate, social worker, patient educators, environmental services
- Laboratory: contracted services (equipment service, backup processing, donor infectious disease testing)



## Step 4: Construction


- CTL Planning Projects:
  - Design & construction of CTL
  - SOP writing
  - Equipment purchasing & install
  - Supply purchasing & organization
  - Staff education & training
  - Process validation plans



# Designing the CTL

- Primary Function: preparing peripheral blood HSC for cryopreservation and infusion, long-term cryostorage
- Key Regulations & Standards: space must be adequate to prevent product mix ups and contamination; environmental monitoring required: temperature, humidity, microbial cultures
- Other Features: positive-pressure to keep contaminants out; seamless surfaces to allow for decontamination, if needed
- Long-term concerns: cryostorage space; manufacturing equipment





Bench with sterile dock, centrifuge



Tank Room



Processing Lab



Anteroom



## Writing CTL SOPs & Forms

- Primary Function: clear instruction for staff, comprehensive documentation, and ultimately positive patient outcomes
- Key Regulations & Standards: document-controlled SOPs and forms for all manufacturing activities; documentation allows tracking of cells from donor to recipient
- Other Features: using online document control system (Policy Tech), all paper processing records
- Long-term concerns: adaptable for future products; record storage & access; cell therapy LIS



### No Comprehensive Resources

- HSC products are not FDA licensed; labs must validate their own processes
- Published Resources:
  - Leemhuis T, et al. Essential requirements for setting up a stem cell processing laboratory. Bone Marrow Transplantation. 2014;49:1098-1105.
  - Areman E and Loper K, editors. *Cellular Therapy: Principles, Methods, and Regulations*, 2<sup>nd</sup> Ed. Bethesda, MD: AABB, 2016.
  - Creer MH, Lemas MV, Mathew AJ. *Practical Handbook of Cellular Therapy Cryopreservation*. Bethesda, MD: AABB, 2015.
  - FACT Accreditation Manual; AABB Standards for Cellular Therapy Services
- A little help from your friends:
  - Policies shared by other institutions
  - Cell therapy lab Google group



HEALTH CARE					ATTACH TAG	
eservation Lab	Autologous				HERE	
I54-7673 arnes-Jewish Plaza	PBSC Storage					
iis, MO 63110	Olorage					
Name:						
55N:						
DOB:						
Protocol#:						
Physician:						
Coord.:		Pati	ent ABO/Rh:		BBTR or SLCH B	В
Diagnosis:			Act wt:			
<u>STORAGE DATA</u> Date:	1	<b>1</b> 2	#3	#4	#5	CUM.
Product #:						
Vol. Processed (MI):						0
Volume (MI):						
Cells/uL:						
Platelet/uL:	0.005.00	0.005.00	0.005.00	0.005.00	0.005.00	
TNC: TNC/Bag:	0.00E+00 #DIV/0!	0.00E+00 #DIV/0!	0.00E+00 #DIV/0!	0.00E+00 #DIV/0!	0.00E+00 #DIV/0!	
TNC/Kg:	w	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!
TNC/Kg/Bag:		#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#51770:
# of Bags:		701770:	nDivio:	noivro:	J.DIVIO:	0
CD34+ /ul.:			* * * * * * * * * * * * * * * * * * * *			
CD34 Absolute: CD34+/Kg:		0.00E+00 #DIV/0!	0.00E+00 #DIV/0!	0.00E+00 #DIV/0!	0.00E+00 #DIV/0!	#DIV/0!
CD34+/Kg/Bag:		#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Viability:						
MNC/kg: Product Neutrophil %:	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	
Product Lymphocyte %:					-	
Product Monocyte %:						
Product ABO/rH: Bag Location:						
Vials:					<del> </del>	
Liters to be processed						
Peripheral CD34/ul: Prediction CD34/Kg:	#DIV/0!	#DIV/0!	#VALUE!	#DIV/0!	#VALUE!	
Product Yield:	w	#DIV/0!	#VALUE!	#DIV/0!	#VALUE!	
CD34+ (Yield) Check:	<b></b>	#DIV/0!	#DIV/0!	#DIV/0!	#DIV/0!	
LOT#/ EXP. Bag Lot #:						
Bag Exp:						
Plasmalyte-A Lot #: Plasmalyte-A Exp:						
DMSO Lot #:						
DMSO Exp: Heparin Lot #:						
Heparin Exp:						
60 ml Syringe Lot#: 14 G Needle Lot#:					+	
3 ml Syringe Lot #:					1	
300 ml bag Lot #: 600 ml bag Lot #:					+	
Sample Port Lot #:					†	

Policies & forms from other centers serve as a starting point or provide ideas.

SANF#RD			Aut	o PBSC	Processi	Validation						
ROGER MARIS			Worksheet B - Calcu			ator	Date:					
CANC	ER CE	NTER	5	Form #CT	L-801-2-C	Issued	: 9/21	Due:				
Cell Therapi	es Lab	(701	1) 234-2234	Revise	d: N/A	Versio	n #: 1					
737 Broadw	vay N, Rte 1	102, Fargo,	ND 58122					DAY:				
				Patier	nt Inform	ation						
Name:							ABO/Rh:					
DOB:							Weight:		kg			
MRN:						CD34 c	dose goal:		x 10^6/kg			
	(Write	or Place Pa	tient Sticker	Here)		We	eight and do	se from Pro	cessing Ord	er		
				Produ	ct Inforn							
Product D	IN (write o	r place st	icker)			Coll	lection Da	te / Time:				
						Exp	iration Da	te / Time:				
					(co	mbined) Pro	oduct Volu	ıme (mL):				
				Product			,					
De	eliver hemat	tology speci	men first. A	dd copies of	result repoi	ts from Bea	ker to patie	nt paper file	as available	2.		
	ABO/Rh:		□ ABO/F	Rh matche	s patient h	nistory.						
			☐ ABO/F	Rh does no	t match;	complete D	eviation F	Report For	m.			
Hei	matocrit:		%	7		D	ifferentia	I - PMNs:		%		
	TNC/uL:		cells/µL	(aka WBC)		D	ifferentia	I - MNCs:		%		
	CD34/μL:		cells/µL		9							
,	Viability:		%	□ Viabilit	v <80%·	contact CT	I Medical	Director 8	Complete			
				x complete								
							Time:		Tech:			
	MRN:  (Write or Place Patient Sticker Here)  (Write or Place Sticker)  (Write or place sticker)  (Collection Date / Time:  (combined)  (co											
	0		=				x	0	/	100		
Produc	t RBC Vol	ume (mL)		Combine	ed Product	Vol (mL)		Hct (%)				
	□ RBC V	/ol. ≥25 m	L in apher	esis produ	ct; comple	ete Proces	s Deviatio	n Report.				
	0.00E+00		=		0		x	0	x	1 000		
Absolute I	Product Ti	VC (cells)	'	Comb.	Product V	ol (mL)	^	TNC/µL		1,000		
	#DIV/0!		=		0.00E+00		/	0	/	10^8		
TNC Dos	e (cells x	10^8/kg)		Absoli	ute Produc	t TNC	1	Weight (kg	)			
	0.00E+00		=		0		Х	0	х	1.000		
Absol	ute CD34	(cells)	'	Comb.	Product V	ol (mL)		CD34/uL		<i>'</i>		
	#DIV/0!	V/0! =					/		/	10^6		
CD34 Dos	se (cells x	10^6/kg)		Absolute Product CD34				Weight (kg	-			
			rmed by: Date:			Time:		Tech:				
		Calo	culations v	erified by:	Date:		Time:		Tech:			
Calcu	lations may	be perform	ed using vali	idated sprea	dsheet. Res	ults must m	atch <u>before</u>	reporting (	or initialing f	orm.		





### Auto-HSCT Processing In a Nutshell...



### Test Apheresis Product

- How many cells are present?
- •Does ABORh match donor?
- •Is there baseline microbial contamination?



### **Prepare Cells For Freezing**

- •Remove excess plasma
- Add cryoprotectant solution
- Divide into aliquots and QC vials
- Repeat culture
- •ISBT 128 labeling



#### Freeze & Store

- •Mechanical freezer or controlled rate freezer
- Liquid/vapor nitrogen storage



#### Thaw & Infuse

- Product release procedure
- •Transport to floor in frozen state
- •Thaw immediately before infusion in body temperature water bath





### CTL Equipment

- Primary Functions: aseptic processing of peripheral blood HSCs, cryopreservation, short & long-term storage
- Key Regulations & Standards: must be adequate to perform the required manufacturing steps
- Other Concerns: redundancy in case of equipment failure
- Key equipment: class I biosafety cabinet, sterile connection device, RF tubing sealer, refrigerated centrifuge, controlled rate freezer, blood bank refrigerator, vapor nitrogen storage tank




## Cryopreservation

- Freezing kills cells through mechanical damage and toxic solute concentrations
- HSCs survive freezing best when cooled 1 to 2 °C per minute in the presence of cryoprotectant solution
- Mechanical freezers may cool cells too rapidly early on, and not rapidly enough as the cells approach the freezer's set temperature
- Controlled rate freezers use temperature probes and a computer program to inject liquid nitrogen into a cooling chamber



### CRF and Example Cooling Curve





# HSCs may be stored indefinitely in liquid/vapor nitrogen (-196°C) freezer







# Supply Chain, Anyone?

- Lab construction is mostly complete, equipment being moved into the space for install
- Where are our freezers???
- Stainless steel shortage → no freezer racks
- Wait it out? Buy from a different company?
   Delay program start?
- Received shipping notification just in time...



### CTL Supplies

- Primary Functions: must be sterile and high quality to prevent patient harm
- Key Regulations & Standards: all critical supplies must meet acceptance criteria and lot numbers recorded in processing records
- Other Concerns: cryopreservation media may require lot-to-lot verification; assessing adequacy of supply vendors
- Key supplies: blood transfer packs, cryopreservation bags, cryovials, cryopreservation media, needle-free bag & vial spikes



# Trying Something New

- Majority of labs make own cryopreservation cocktail
  - Dimethyl sulfoxide (DMSO) +/hydroxyethyl starch (HES)
- Requires lot verification, opportunity for contamination
- Cheap, trusted → INERTIA

- USP-grade product available
- Cost \$\$\$
- No lot verification, can transfer with sterile connection device
- Great fit for Sanford



### Staff Education & Training

- Primary Functions: produce competent staff and quality patient care
- Key Regulations & Standards: staff are adequately trained to perform assigned tasks; receive annual HSCT-related education
- Other Concerns: CTL processing not included in standard technologist training programs; finding a host lab may be difficult
- Training Activities: virtual lab visit, in-person lab training, AABB Certificate in Cellular Therapies course, medical director lectures, participation in program planning and validations



### Validation Plans

- Primary Function: demonstrate process/equipment performs as expected and meets facility needs
- Key Regulations & Standards: validations of equipment, processes, and tests are required
- Other Concerns: must design own protocol and acceptance criteria; obtaining materials
- Major Validations: Cryopreservation & cryostorage, aseptic processing, apheresis collection, sterility culture, CD34 enumeration by flow cytometry, labeling (quality & stock)



### Step 5: Practice and Revise

- Lab construction complete
- Installed & qualified equipment
- Began lab process validations
- Participated in joint mock runs

Rewriting
Revise, Revise
Second Draft
Final Drafts
About Revisir
On Revising
On Revision

These are learning opportunities;

failure is sometimes the best teacher!

William Germano



# A short list of lessons learned during mock & validation runs...

- Verify product volumes by weighing them.
- Don't expect slaughterhouse bovine blood to be sterile...
- Don't use rigid centrifuge balance weights.
- We should have bought bigger hoods...


- Freezing bags alone in the cassette yields better freezing curves
- Incidentally, we now have half the freezer storage space...
- Writing validation acceptance criteria is hard.
- There are different types of liquid nitrogen cylinders, and yes, it matters!





### Trust, But Verify

- Apheresis MNC product collected by blood center
- 400 mL was written on bag label
- When volume reducing ahead of cryopreservation, was about 100 mL "short"
- Blood center staff had added plasma volume twice—real volume was only 300 mL
- Adjusted our SOP and processing records to include weight checks to confirm volume




### Step 6: The First Transplant

- 55 y.o. man from NW Minnesota with multiple myeloma
- Underwent 2 days of apheresis collection
- Received high-dose melphalan on 10/20/21
- HSC infusion scheduled on 10/21/21



### The Cells Are Stuck...

- The first bag is thawed, spiked and hung for infusion by gravity
- PICC line was kinked intravascularly—cells would not flow!
- Took remaining frozen bags back to lab for thaw & transfer to syringes under hood
- Cells pushed in via infusion pump



## The Long Wait...

10 days after transplant:

```
    WBC 0.1 x K/uL (Ref. 4.0 – 11.0 K/uL)
```

- Hgb 10.4 g/dL (Ref. 13.5 17.5 g/dL)
- Plt 11 K/uL (Ref. 140 400 K/uL)



- New onset fever (100.6F)
- C-reactive protein spiking to 20.8 mg/L (Ref. <5 mg/L)</li>

### Houston, we have lift off!

 Engraftment of neutrophils and platelets on day +12




- Discharged on 11/4/21
- 8 successful auto-HSC transplants, and counting!

	10/31/2021 0507		11/1/2021 0617		11/2/2021 0445		11/3/2021 0620		11/4/2021 0600		11/5/2021 0804	
CBC												
WBC	0.1 *	¥	0.5 *	¥	1.5 *	¥	3.3 *	¥	3.2 *	¥	3.5 *	-
RBC	3.59	÷	3.39 *	÷	3.25 *	÷	3.40 *	÷	3.36 *	÷	3.60 *	-
Hemoglobin	10.4	~	10.0 *	¥	9.6 *	¥	9.8 *	¥	9.8 *	¥	10.1 *	-
Hematocrit	30.3	-	28.6 *	-	27.3 *	-	28.8 *	-	28.5 *	-	30.2 *	-
MCV	84.4		84.4 *		84.0 *		84.7 *		84.8 *		83.9 *	
MCH	29.0		29.5 *		29.5 *		28.8 *		29.2 *		28.1 *	
MCHC	34.3		35.0 *		35.2 *		34.0 *		34.4 *		33.4 *	
RDW-CV	14.5		14.7 *		14.7 *		15.1 *		15.3 *		15.8 *	^
RDW-SD	45.3		45.4 *		45.4 *		46.5 *		47.2 *		48.1 *	
Platelet Count	11	÷	18*	÷	32 *	-	56*	÷	87 *	÷	149 *	
MPV	9.7		10.1 *		10.6 *		10.8 *		10.6 *		11.0 *	



# Next Steps...

- Building our quality system
- Refining SOPs and forms
- Training additional CTL techs
- Preparing for allogeneic transplants (July 2022)
- Preparing for FACT accreditation (2023-24)





### Words of Wisdom – Lab Style

- Be flexible, things will change from the initial plan. And that's OK.
- Roll with the Punches! Things outside of your control will go wrong from time to time.
- Get the bigger hood. ©
- Become friends with the IT department! ©
- Utilize your resources. You don't always have to re-invent the wheel.
- Look ahead to what we want to become, but don't over/under prepare for it; find a happy medium.







Heartfelt thanks to:

Kayleigh Buescher, MLS

and

Stephanie Hidalgo, MLS

First Cellular Therapy Technologists in North Dakota!



### References

- National Cancer Institute Surveillance, Epidemiology, and End Results Program (SEER). Cancer Stat Facts. <a href="https://seer.cancer.gov/statfacts/">https://seer.cancer.gov/statfacts/</a>. Accessed 3/17/2022.
- United States Census Bureau. Quick Facts. <u>https://www.census.gov/quickfacts/fact/map/ND,US/PST045221. Accessed 3/17/2022</u>.
- US Code of Federal Regulations, Title 21, Section 1271. Good Tissue Practice. <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271</a>. Accessed 4/15/22.
- Hematopoietic Cellular Therapy Accreditation Manual, 8<sup>th</sup> Edition, Version 8.2. Foundation for the Accreditation of Cellular Therapy, December 2021.





### Questions?

• Email: nicholas.gau@sanfordhealth.org

